Evaluation
BenariWell Demo & Evaluation Terms
These terms apply to BenariWell demonstration and evaluation access. Reading this website does not require you to accept them.
Before you accept
BenariWell demonstration access is provided for evaluation purposes using synthetic information only.
BenariWell and its associated software, branding, product design, documentation and confidential implementation materials remain subject to applicable intellectual-property and confidentiality rights.
Do not enter real patient or confidential clinical information.
The agreement control is never pre-selected. Acceptance requires an affirmative action by the evaluator.
Full terms — version 1.0.0, effective 2026-02-01
1. Evaluation-only access
Demonstration access is provided so that you can evaluate BenariWell using synthetic information. It is not a clinical service, not a production account and not authorisation to use BenariWell in patient care.
BW-TERM-001 · Needs legal review
2. Permitted use
You may explore the synthetic demonstration workspace made available to you, for the purpose of evaluating whether BenariWell suits your service.
BW-TERM-002 · Needs legal review
3. Confidentiality
Non-public information you see during evaluation, including unreleased functionality, documentation and commercial information, is confidential and should not be disclosed outside your organisation without permission.
BW-TERM-003 · Needs legal review
4. Intellectual property ownership
BenariWell software, branding, product design, written content and demonstration fixtures remain the property of their respective owners. Evaluation access transfers no ownership and grants no licence beyond evaluation.
BW-TERM-004 · Needs legal review
5. Account security and no credential sharing
Demonstration accounts are individual. You will not share your credentials, and you will tell us if you believe your access has been used by someone else.
BW-TERM-005 · Needs legal review
6. No real patient data
You will not enter real patient, identifiable or confidential clinical information into the demonstration. Real-patient processing is technically blocked.
BW-TERM-006 · Needs legal review
7. No unauthorised redistribution
You will not redistribute BenariWell material, documentation or demonstration exports outside the evaluation described above.
BW-TERM-007 · Needs legal review
8. No attempts to obtain source code or bypass access controls
You will not attempt to obtain BenariWell source code, internal prompts, configuration or secrets, and you will not attempt to bypass access controls.
BW-TERM-008 · Needs legal review
9. Reverse engineering
Subject to applicable law, you will not reverse engineer, decompile, extract internal implementation from, or circumvent technical controls in BenariWell. Wording alone is not relied on as a security control.
BW-TERM-009 · Needs legal review
10. Copying confidential documentation and implementation detail
Confidential BenariWell documentation and internal implementation detail must not be copied, extracted or reproduced outside the evaluation.
BW-TERM-010 · Needs legal review
11. Feedback
Product feedback you choose to give may be considered when BenariWell is developed. Giving feedback does not transfer ownership of BenariWell to you, and BenariWell does not claim ownership of your unrelated clinical or organisational intellectual property. Feedback marked organisation confidential is kept confidential.
BW-TERM-011 · Needs legal review
12. Termination and expiry
Demonstration access is time limited and may be renewed, ended or withdrawn at any time. When access ends, protected evaluator access stops; access and acceptance records are retained under the governed retention policy.
BW-TERM-012 · Needs legal review
13. Disclaimers appropriate to synthetic evaluation
Demonstration content is fictional. Outputs are illustrative only, are not clinical records and must not be used in patient care.
BW-TERM-013 · Needs legal review
14. No ownership, shares or equity
Using, evaluating, testing, giving feedback on, collaborating with, piloting or paying for BenariWell does not give you or your organisation ownership of BenariWell, shares, equity, beneficial ownership, or any intellectual-property right in BenariWell. Final contractual wording remains subject to legal review.
BW-TERM-015 · Needs legal review
15. No resale, white-labelling or exclusivity
Evaluation access does not allow you to resell, rebrand, white-label or grant others access to BenariWell, and gives no exclusivity or territory rights. Any such arrangement would require a separate written agreement.
BW-TERM-016 · Needs legal review
16. Governing law and jurisdiction
[Governing law — for legal review] / [Jurisdiction — for legal review]
BW-TERM-014 · Needs legal review
Screenshots, recording and exports
Screenshots are permitted for your internal evaluation only, and should not be shared outside your organisation.
Please do not record this demonstration without prior permission.
Every permitted export is marked BENARIWELL · SYNTHETIC DEMONSTRATION · NOT A CLINICAL RECORD, and the marking cannot be removed.
BenariWell cannot technically prevent screenshots or external screen recording. The screenshot and recording positions are policy statements recorded against the evaluation, supported by watermarking and controlled disclosure.
